In 2015, The influence of cannabinoids on generic traits of neurodegeneration BACKGROUND: Through multiple lines of evidence, this evolutionarily conserved neurosignalling system has shown neuroprotective capabilities and is, therefore, a potential target for neurodegenerative disorders. This review details the mechanisms of neurodegeneration and highlights the beneficial effects of cannabinoid treatment. You can read the full article …
In 2007, Alzheimer’s disease; taking the edge off with cannabinoids? BACKGROUND: The evidence supporting a potential role for the cannabinoid system as a therapeutic target for the treatment of Alzheimer’s disease will be reviewed herewith. You can read the full article here => https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2190031/.
In 2016, CB2 Cannabinoid Receptor As Potential Target against Alzheimer’s Disease BACKGROUND: This review discusses available data regarding the role of CB2 receptors in AD and the potential usefulness of specific agonists of these receptors against AD.. You can read the full article here => https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885828/?report=classic
In 2017, Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target BACKGROUND: review the role of eCB system in two chronic neurodegenerative diseases, in which the neuroprotective effects following CB receptors modulation have been reported in different studies. Specifically, we will focus on the role of CB2 receptors and their agonists, as …
In 2004, Neuroprotective effect of cannabidiol, a non‐psychoactive component from Cannabis sativa, on β‐amyloid‐induced toxicity in PC12 cells BACKGROUND: The aim of the present study is to evaluate the possible neuroprotective effect of cannabidiol on β‐amyloid‐induced neurotoxicity. For this purpose we evaluated the effect of cannabidiol on cell viability, reactive oxygen species (ROS) formation and membrane lipoperoxidation, …
In 2016, Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids BACKGROUND: We hypothesized that proteotoxicity in nerve cells themselves may initiate an inflammatory response that can lead directly to their death and contribute to overall inflammation in the CNS. The following experiments identify the molecular basis of this inflammatory response using a human CNS nerve …
In 2014, Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice BACKGROUND: The non-psychoactive phytocannabinoid cannabidiol (CBD) exerts neuroprotective, anti-oxidant and anti-inflammatory effects and promotes neurogenesis. CBD also reverses Aβ-induced spatial memory deficits in rodents. You can read the full article here => http://link.springer.com/article/10.1007%2Fs00213-014-3478-5
In 2006, A Molecular Link Between the Active Component of Marijuana and Alzheimer’s Disease Pathology BACKGROUND: Here, we demonstrate that the active component of marijuana, Δ9-tetrahydrocannabinol (THC), competitively inhibits the enzyme acetylcholinesterase (AChE) as well as prevents AChE-induced amyloid β-peptide (Aβ) aggregation, the key pathological marker of Alzheimer’s disease. You can read the full article here => https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2562334/